Low Occurrence of Tuberculosis Drug Resistance among Pulmonary Tuberculosis Patients from an Urban Setting, with a Long-Running DOTS Program in Zambia.

Tuberculosis Research and Treatment
Chanda MulengaLeen Rigouts

Abstract

We set out to determine the levels of Mycobacterium tuberculosis resistance to first- and second-line TB drugs in an urban population in Zambia. Sputum samples were collected consecutively from all smear-positive, new and previously treated patients, from four diagnostic centres in Ndola between January and July 2006. Drug susceptibility testing was performed using the proportion method against four first- and two second-line TB drugs. Results. Among 156 new cases, any resistance was observed to be 7.7%, monoresistance to isoniazid and rifampicin was 4.5% and 1.3%, respectively. Of 31 retreatment cases, any resistance was observed to be 16.1%, monoresistance to isoniazid and rifampicin was 3.3% for each drug, and one case of resistance to both isoniazid and rifampicin (multidrug resistance) was detected. No resistance to kanamycin or ofloxacin was detected. Conclusion. Although not representative of the country, these results show low levels of drug resistance in a community with a long-standing DOTS experience. Resource constrained countries may reduce TB drug resistance by implementing community-based strategies that enhance treatment completion.

References

Apr 1, 1992·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·J S JarallahS A al-Shammari
Sep 1, 1995·American Journal of Respiratory and Critical Care Medicine·C M NolanS V Goldberg
Feb 1, 1996·American Journal of Respiratory and Critical Care Medicine·M LutfeyB N Kreiswirth
Dec 24, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·F MarchG Prats
Feb 7, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S S MunsiffT R Frieden
Jun 25, 1998·American Journal of Respiratory and Critical Care Medicine·R RidzonI M Onorato
Feb 2, 1999·American Journal of Respiratory and Critical Care Medicine·L SandmanS Bonk
Jan 25, 2000·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S Ramaswamy, J M Musser
Oct 24, 2007·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·A UmubyeyiF Portaels
Jun 27, 2008·BMC Microbiology·Susanne HomolkaStefan Niemann

❮ Previous
Next ❯

Citations

Sep 17, 2013·Tropical Medicine & International Health : TM & IH·Nathan KapataAlimuddin Zumla
Aug 1, 2015·Tropical Medicine & International Health : TM & IH·Nathan KapataHelen Ayles
Nov 24, 2012·The Lancet Infectious Diseases·Gyanshankar P Mishra

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

Cytel
Probe Accuprobe System
SAS
StatXact
Epi Info
Gen

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.